Olix Receives Approval for Clinical Trial Modification of Non-Alcoholic Steatohepatitis Treatment in Australia

Olix announced on the 30th that it has received approval from the Alfred Human Research Ethics Committee in Australia for the modification of the Phase 1 clinical trial plan of OLX75016 (a treatment for non-alcoholic steatohepatitis) in Australia. The expected completion date is December 19 next year.

This content was produced with the assistance of AI translation services.